Dr. Andrea Sboner

Battling a deadly blood cancer, a New Jersey woman gets a second chance — thanks to precision medicine

Molecular characteristics detected in prostate cancers can provide clues that help predict how the disease will progress, according to new research from investigators at Weill Cornell Medicine and NewYork-Presbyterian.

A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.